Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ Airway Clearance System, announced it has closed an oversubscribed $5 million funding round to accelerate commercial expansion and clinical adoption across the U.S.
The investment was led by Edge Medical Ventures, with participation from the New Jersey Economic Development Authority, Broadfin Holdings, Consensus Business Group, and angel investors. The financing will support U.S. commercial growth, ongoing clinical research, product development, and broader patient access to the LibAirty™ system.
Designed for individuals living with chronic lung conditions, LibAirty™ delivers at-home airway clearance therapy through a daily treatment regimen. The company says the system has demonstrated the ability to clear twice as much sputum as conventional therapies while enhancing user comfort and satisfaction. Since its commercial launch in late 2025, LibAirty™ has seen strong uptake from both patients and clinicians.
As part of the funding, Kevin Kotler, General Partner of Broadfin Holdings, and Elad Duschak, Strategic Advisor to Consensus Business Group for Healthcare, have joined the company’s Board of Directors.
Synchrony Medical will continue expanding its U.S. team and operations from its Jersey City headquarters. The financing includes $1 million from the New Jersey Economic Development Authority through the New Jersey Innovation Evergreen Fund’s co-investment with Edge Medical Ventures, supporting the company’s growth within the state.
Founded through Edge Medical Ventures’ EdgeLabs accelerator program and developed in collaboration with pulmonologists at Sheba Medical Center, the LibAirty™ system is supported by the Israel Innovation Authority. The company also maintains operations in Or Yehuda, Israel.
KEY QUOTES:
“This funding enables us to advance our mission of delivering meaningful clinical outcomes by bringing effective, easy-to-use airway clearance into more homes and empowering patients to manage their respiratory health. Supported by our exceptional investors and new board members, we’re well positioned to scale our U.S. market presence, expand our clinical evidence base, and advance product innovation.”
Anat Shani, CEO, Synchrony Medical
“The LibAirty™ System, with its proven clinical advantage, is poised to disrupt a market with high demand and strong growth. We look forward to working with the team to scale nationwide and create meaningful value for both patients and shareholders.”
Kevin Kotler, General Partner, Broadfin Holdings
“Synchrony exemplifies the type of innovation we seek to support, addressing an unmet clinical need through strong clinical foundations and a clear path to transforming patient care. This demonstrates how Edge’s transatlantic presence, combined with the company’s proven execution capabilities, can establish a new standard of care and bring it to market.”
Shai Policker, Chairman, Synchrony Medical; Managing Partner, Edge Medical Ventures
“As partners of EdgeLabs (formerly MEDX Xelerator), we are proud to support Synchrony from its early stages of development and witness its remarkable progress. We are pleased to continue supporting this important, high-impact medical innovation and make it more widely available for patients.”
Vincent Tchenguiz, Chairman, Consensus Business Group
